-

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Avaya Holdings Corp. (AVYA)

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Avaya Holdings Corp. (NYSE: AVYA) between November 22, 2021 and November 29, 2022, for violations of the Securities Exchange Act of 1934. Avaya purports to be a "global leader in digital communications products, solutions, and services for businesses of all sizes delivering its technology predominately through software and services."

What Now: Similarly situated shareholders may be eligible to participate in the class action against Avaya. Shareholders who want to act as lead plaintiff for the class must file their papers by March 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: Avaya Holdings Corp. (AVYA) Failed to Disclose Deficient Internal Control Over Financial Reporting

According to the complaint, during the class period, defendants failed to disclose that the Company's internal control over financial reporting was deficient and the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program.

On July 28, 2022, Avaya announced the termination of its CEO and its preliminary Q3 2022 financial results that included expected revenues and adjusted EBITDA well below previously given guidance and an unqualified but "significant" impairment charge. Avaya also withdrew its 2022 guidance. On this news, Avaya's stock price fell $1.19 per share, or almost 57%, to close at $0.90 per share on July 29, 2022.

Then, on August 9, 2022, Avaya announced there was a substantial doubt about its ability to continue as a going concern and its Audit Committee commenced internal investigations into circumstances involving the Company's financial results for the quarter and matters raised by a whistleblower. On this news, Avaya's stock fell to $0.61 per share, or over 45%.

Finally, on November 30, 2022, Avaya disclosed material weaknesses in the Company's internal control over finance and stated that the Company's Annual Report on Form 10-K for its fiscal year 2021 ended September 30, 2021, should no longer be relied upon. On this news, Avaya's stock fell 14.28%, to close at $0.96 per share.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Avaya Holdings Corp. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:AVYA

Release Summary
Avaya Holdings Corp. (AVYA) Failed to Disclose Deficient Internal Control Over Financial Reporting
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800)...

Investor Notice: Robbins LLP Informs Investors of the Gemini Space Station, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gemini Space Station, Inc. (NASDAQ: GEMI) Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini Space Station, Inc. securities between September 12, 2025 and February 17, 2026. Gemini was founded to develop and operate a cryptocurrency platform. For more information, s...

uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? September 24, 2025 – October 31, 2025 W...
Back to Newsroom